Clovis Oncology

Oncology Compound Licencing Company

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.

Founded in 2009
Total money raised: $357M


80301 2525 28th Street
Suite 100

Updated on Jan 31, 2014
Clovis Oncology at CrunchBase
Andrew Allen Founder
Patrick Mahaffy Founder, CEO & President
Gillian C. Ivers-Read Executive Vice President, Technical Operations and Chief Regulatory Officer
Erle T. Mast Executive Vice President and Chief Financial Officer
Steven L. Hoerter Senior Vice President, Commercial
Brian Atwood Board Member
Jim Blair Boards of Directors
Ginger Graham Baord of Directors
Edward J. McKinley Baord of Directors
M. James Barrett Board of Directors
Keith Flaherty Baord of Directors
Paul Klingenstein Baord of Directors
Dr. Thorlef Spickschen Baord of Directors
Julie Hambleton Vice President, Clinical Development

November, 2013

Clovis Oncology raised $192M in private_equity round


Clovis Oncology acquired EOS (Ethical Oncology Science) for $200M

Clovis Oncology Acquires EOS (Ethical Oncology Science) S.p.A. to Gain Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor

January, 2012

Clovis Oncology invested $4M in Avila Therapeutics as unattributed round

November, 2011

Clovis Oncology IPO
Stock symbol: NASDAQ:CLVS

June, 2011

Clovis Oncology raised $20M in convertible round


May, 2009

Clovis Oncology raised $145M in private_equity round from Domain Associates, New Enterprise Associates, Versant Ventures, Aberdare Ventures, Abingworth, Frazier Healthcare Ventures, and ProQuest Investments

Clovis Oncology (Boulder, CO) an entity focused on licensing or acquiring rights to oncology compounds in all stages of clinical development


Clovis Oncology was founded in 2009